• T Fonnes, J Trovik, P-Hd Edqvist, K E Fasmer, J Marcickiewicz, S Tingulstad, A C Staff, L Bjørge, F Amant, I S Haldorsen, Hmj Werner, L A Akslen, I L Tangen, and C Krakstad.
• Department of Clinical Science, Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway.
• BJOG. 2018 Dec 1; 125 (13): 1695-1703.

ObjectiveCorrect preoperative identification of high-risk patients is important to optimise surgical treatment and improve survival. We wanted to explore if asparaginase-like protein 1 (ASRGL1) expression in curettage could predict lymph node metastases and poor outcome, potentially improving preoperative risk stratification.DesignMulticentre study.SettingTen hospitals in Norway, Sweden and Belgium.PopulationWomen diagnosed with endometrial carcinoma.MethodsASRGL1 expression in curettage specimens from 1144 women was determined by immunohistochemistry.Main Outcome MeasuresASRGL1 status related to disease-specific survival, lymph node status, preoperative imaging parameters and clinicopathological data.ResultsASRGL1 expression had independent prognostic value in multivariate survival analyses, both in the whole patient population (hazard ratio (HR) 1.63, 95% CI 1.11-2.37, P = 0.012) and in the low-risk curettage histology subgroup (HR 2.54, 95% CI 1.44-4.47, P = 0.001). Lymph node metastases were more frequent in women with low expression of ASRGL1 compared with women with high ASRGL1 levels (23% versus 10%, P < 0.001), and low ASRGL1 level was found to independently predict lymph node metastases (odds ratio 2.07, 95% CI 1.27-3.38, P = 0.003).ConclusionsLow expression of ASRGL1 in curettage independently predicts lymph node metastases and poor disease-specific survival.Tweetable AbstractLow ASRGL1 expression in curettage predicts lymph node metastasis and poor survival in endometrial carcinoma.© 2018 Royal College of Obstetricians and Gynaecologists.

26 keywords...

hide…